Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Short Interest Update

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totalling 5,000 shares, a drop of 99.4% from the March 15th total of 868,800 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 243,500 shares, the days-to-cover ratio is currently 0.0 days.

Quoin Pharmaceuticals Price Performance

NASDAQ QNRX traded down $0.09 on Monday, hitting $5.28. 66,354 shares of the stock were exchanged, compared to its average volume of 91,809. The company has a market capitalization of $3.11 million, a PE ratio of -1.30 and a beta of 1.89. The business’s fifty day moving average is $9.89 and its 200 day moving average is $17.39. Quoin Pharmaceuticals has a 52 week low of $5.04 and a 52 week high of $54.95.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($12.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($17.50) by $5.25. Analysts predict that Quoin Pharmaceuticals will post -2.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Altium Capital Management LLC bought a new position in Quoin Pharmaceuticals during the 4th quarter worth $184,000. Renaissance Technologies LLC grew its stake in shares of Quoin Pharmaceuticals by 244.1% in the fourth quarter. Renaissance Technologies LLC now owns 133,122 shares of the company’s stock valued at $87,000 after acquiring an additional 94,431 shares in the last quarter. Boothbay Fund Management LLC bought a new position in Quoin Pharmaceuticals during the fourth quarter worth about $53,000. Finally, Apollon Wealth Management LLC acquired a new stake in Quoin Pharmaceuticals in the 4th quarter worth about $52,000. 8.63% of the stock is owned by institutional investors.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.